Latest clinical findings of the ConVerd's subsidiary self-develped NKG2D-CAR-NK published in Molecular Therapy
Column:Company News Time:2019-09-21
The latest results of a NKG2D-CAR-NK's clinical stuy, conducted by ConVerd's subsidiary and a team led by Hu Xv who is the president of the 3rd hospital of Guangzhou Medical University, were publishe in the journal, Molecular Therapy.

Hangzhou Youshan Biomedical Co., Ltd., the subsidiary of Hangzhou ConVerd Co., Ltd, cooperate with the team led by Hu Xv, the president of the 3rd hospital of Guangzhou Medical University, to conduct a clinical study of NKG2D-CAR modified NK cells in the treatment of patients with advanced colorectal cancer. The purpose of this clinical study is to evaluate the safety and effecacy of the CAR-NK. The dose escalating has been completed in three patients. The results were published in Molecular Therapy. This article can be accessed at https://www.sciencedirect.com/science/article/abs/pii/S1525001619300978 

Previous: End